Anders Sundström
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anders Sundström has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Rickard Ljung
Division of Use and Information, Swedish Medical Products Agency, Uppsala, Sweden
9 shared publications - Björn Zethelius
Use and Information Division, Swedish Medical Products Agency, Uppsala, Sweden
5 shared publications - Sofia Attelind
Department of Medical Sciences, Clinical Pharmacogenomics Uppsala University Uppsala Sweden
5 shared publications - Björn Wettermark
Department of Pharmacy Uppsala University Uppsala Sweden
3 shared publications - Karl Mikael Kälkner
Pharmacoepidemiology and Analysis Department, Swedish Medical Product Agency, Uppsala, Sweden
3 shared publications Marja-Leena Nurminen
Pharmacoepidemiology and Analyses Department, Swedish Medical Products Agency , Uppsala
3 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (10) , e70482
High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden—A Register‐Based Study
Purpose: This study aims to assess the risk of metabolic side effects among paediatric new users of antipsychotics in Sweden, focusing on differences between substances and sexes. Methods: Children aged 5–17 years, who were new users of antipsychotics between 2014 and 2021, were identified using Swedish national health registers. Cox' models were fitted for children during first treatment with an antipsychotic, excluding those with eating disorders, yielding hazard ratios (HRs) for metabolic side effects with 95% confidence intervals (CIs). Results: A total of 5441 children were new users of antipsychotics. Of these, 399 (7.3%; 42% girls) received a new diagnosis or new treatment indicating a metabolic side effect, of which 139 cases during first‐line treatment and without an eating disorder diagnosis. Obesity was the most common metabolic side effect, accounting for 69% of the cases. In girls, significantly increased risks were observed for aripiprazole (HR 3.52, 95% CI 1.58–7.80), olanzapine (HR 6.99, 95% CI 2.34–20.93) and quetiapine (HR 4.87, 95% CI 1.97–12.04), compared with risperidone. Younger girls had higher risks. In boys, a significantly increased risk was found for aripiprazole (HR 2.21, 95% CI 1.37–3.56). Conclusion: The overall risk of metabolic side effects is considerable, with higher relative risks in girls, especially younger girls. These findings highlight the need for carefully considered treatment and attentive monitoring when initiating antipsychotics in children.
- 22 September 2026
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (10) , e70482
Open AccessHigh Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden—A Register‐Based Study
Purpose: This study aims to assess the risk of metabolic side effects among paediatric new users of antipsychotics in Sweden, focusing on differences between substances and sexes. Methods: Children aged 5–17 years, who were new users of antipsychotics between 2014 and 2021, were identified using Swedish national health registers. Cox' models were fitted for children during first treatment with an antipsychotic, excluding those with eating disorders, yielding hazard ratios (HRs) for metabolic side effects with 95% confidence intervals (CIs). Results: A total of 5441 children were new users of antipsychotics. Of these, 399 (7.3%; 42% girls) received a new diagnosis or new treatment indicating a metabolic side effect, of which 139 cases during first‐line treatment and without an eating disorder diagnosis. Obesity was the most common metabolic side effect, accounting for 69% of the cases. In girls, significantly increased risks were observed for aripiprazole (HR 3.52, 95% CI 1.58–7.80), olanzapine (HR 6.99, 95% CI 2.34–20.93) and quetiapine (HR 4.87, 95% CI 1.97–12.04), compared with risperidone. Younger girls had higher risks. In boys, a significantly increased risk was found for aripiprazole (HR 2.21, 95% CI 1.37–3.56). Conclusion: The overall risk of metabolic side effects is considerable, with higher relative risks in girls, especially younger girls. These findings highlight the need for carefully considered treatment and attentive monitoring when initiating antipsychotics in children.
- Open Access
- 5 August 2026
- Published by Springer Nature in BMC Primary Care
- Vol. 27 (1) , 289
Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey
Background: Obesity is a growing global health burden, previously with few effective treatments. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally approved for diabetes but are increasingly prescribed for treatment of overweight and obesity. The increasing expenditure has led to ethical debates surrounding the utilization of these drugs. Few studies have investigated the attitudes to GLP-1 RAs among prescribing physicians. This study aimed to assess the attitudes to GLP-1 RAs for treatment of overweight and obesity among Swedish primary care physicians. Methods: This was a cross-sectional survey with descriptive quantitative analysis and thematic analysis of free-text responses. A mix of multiple-choice questions and rating scales, including the Likert scale was employed. The study was conducted in October 2024 among physicians working in primary care in the Swedish regions of Gävleborg, Uppsala, Västernorrland, Västmanland and Örebro. The survey was distributed through the Drug and Therapeutics Committees (DTCs) in the regions. Results: The 190 responses yielded a response rate of 28%. Of these, 163 responses could be included in the final analysis. Almost all respondents (98%) agreed that GLP-1 RAs are effective drugs for treating obesity, and 91% believed they will be important for obesity treatment in the future. Main identified barriers for prescribing GLP-1 RAs were high patient co-payment (69%) and low drug availability due to supply shortages at the time of conducting this survey (86%). Conclusion: Physicians working in primary care in Sweden consider GLP-1 RAs effective for treating obesity and believe these drugs will play an important role in obesity treatment in the future. These findings should be interpreted in the light of the low response rate and possible self-selection bias.
- 5 August 2026
- Published by Springer Nature in BMC Primary Care
- Vol. 27 (1) , 289
Open AccessAttitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey
Background: Obesity is a growing global health burden, previously with few effective treatments. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally approved for diabetes but are increasingly prescribed for treatment of overweight and obesity. The increasing expenditure has led to ethical debates surrounding the utilization of these drugs. Few studies have investigated the attitudes to GLP-1 RAs among prescribing physicians. This study aimed to assess the attitudes to GLP-1 RAs for treatment of overweight and obesity among Swedish primary care physicians. Methods: This was a cross-sectional survey with descriptive quantitative analysis and thematic analysis of free-text responses. A mix of multiple-choice questions and rating scales, including the Likert scale was employed. The study was conducted in October 2024 among physicians working in primary care in the Swedish regions of Gävleborg, Uppsala, Västernorrland, Västmanland and Örebro. The survey was distributed through the Drug and Therapeutics Committees (DTCs) in the regions. Results: The 190 responses yielded a response rate of 28%. Of these, 163 responses could be included in the final analysis. Almost all respondents (98%) agreed that GLP-1 RAs are effective drugs for treating obesity, and 91% believed they will be important for obesity treatment in the future. Main identified barriers for prescribing GLP-1 RAs were high patient co-payment (69%) and low drug availability due to supply shortages at the time of conducting this survey (86%). Conclusion: Physicians working in primary care in Sweden consider GLP-1 RAs effective for treating obesity and believe these drugs will play an important role in obesity treatment in the future. These findings should be interpreted in the light of the low response rate and possible self-selection bias.
- Open Access
- 28 May 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (9) , 3246-3256
Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study
Aim: We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods: We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish Medical Products Agency. Two hundred one cases (43% women, 91% Swedish) were compared with 4891 Swedish population controls. Analyses were performed on two candidate variants in coagulation factor II (rs1799963) and coagulation factor V (rs6025), on 14 prespecified candidate genes and across the whole genome. To support the findings, we conducted an observational register study of the Swedish general population with/without a diagnosis of thrombophilia and the risks of venous thromboembolism after SARS‐CoV‐2 vaccination. Results: In the GWAS, the main findings were that the candidate variants of coagulation factors II rs1799963 and V rs6025 were significantly associated with venous thromboembolism (odds ratio [OR] 2.4 [95% confidence interval (CI) 1.2–4.8], p = .015 and OR 1.8 [95% CI 1.3–2.6], p = .0022). No genetic marker passed the significance threshold in the candidate gene analysis or the full genome‐wide analysis. In the register study, people with a thrombophilia diagnosis had a five‐fold elevated risk of venous thromboembolism within 42 days after vaccination, adjusted for potential confounders, OR 5.06 [95% CI 3.98–6.44]. Conclusion: Well‐characterized genetic variants in the genes of coagulation factors II and V were associated with thromboembolism after SARS‐CoV‐2 immunization. Further research is recommended to elucidate their potential role in vaccine‐related thromboembolic events.
- 28 May 2026
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (9) , 3246-3256
Open AccessRisk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study
Aim: We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods: We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish Medical Products Agency. Two hundred one cases (43% women, 91% Swedish) were compared with 4891 Swedish population controls. Analyses were performed on two candidate variants in coagulation factor II (rs1799963) and coagulation factor V (rs6025), on 14 prespecified candidate genes and across the whole genome. To support the findings, we conducted an observational register study of the Swedish general population with/without a diagnosis of thrombophilia and the risks of venous thromboembolism after SARS‐CoV‐2 vaccination. Results: In the GWAS, the main findings were that the candidate variants of coagulation factors II rs1799963 and V rs6025 were significantly associated with venous thromboembolism (odds ratio [OR] 2.4 [95% confidence interval (CI) 1.2–4.8], p = .015 and OR 1.8 [95% CI 1.3–2.6], p = .0022). No genetic marker passed the significance threshold in the candidate gene analysis or the full genome‐wide analysis. In the register study, people with a thrombophilia diagnosis had a five‐fold elevated risk of venous thromboembolism within 42 days after vaccination, adjusted for potential confounders, OR 5.06 [95% CI 3.98–6.44]. Conclusion: Well‐characterized genetic variants in the genes of coagulation factors II and V were associated with thromboembolism after SARS‐CoV‐2 immunization. Further research is recommended to elucidate their potential role in vaccine‐related thromboembolic events.
- Open Access
- 27 April 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (5) , 133
Authors response to the comments by Muhammad Salman, Muhammad Hammad Chola and Muhammad Hasan on our paper “prescribing patterns of glucagon like peptide-1 receptor agonists in the Swedish capital region: a register-based cross-sectional study”
- 27 April 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (5) , 133
Open AccessAuthors response to the comments by Muhammad Salman, Muhammad Hammad Chola and Muhammad Hasan on our paper “prescribing patterns of glucagon like peptide-1 receptor agonists in the Swedish capital region: a register-based cross-sectional study”
- Open Access
- 10 January 2026
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 35 (5) , 1487-1496
Drug utilisation of antipsychotics and lithium in Sweden 2008–2021 – a nationwide study of children aged 5–17 years
Antipsychotics are mainly used for severe psychiatric disorders. Risperidone is the only antipsychotic approved for younger children. Aripiprazole is approved for older children, ziprasidone and lurasidone for adolescents. To describe paediatric utilisation of antipsychotic drugs in Sweden. Dispensations of antipsychotic drugs to children aged 5–17 years from 2008 to 2021 were analysed using the National Prescribed Drug Register and recorded diagnoses were obtained from the National Patient Register. Overall, dispensations of antipsychotics to children increased from 16.7 to 36.9/10,000 between 2008 and 2021. The increase was larger in girls, from 12.3 to 36.6/10,000. New users of antipsychotics increased by 121% in the same period, from 7.9 to 17.5/10.000. In 2019, in children aged 12–17, 63% of girls and 71% of boys were dispensed had at least three dispensations of antipsychotics, while the corresponding proportion in children aged 5–11 were 52% for girls and 63% for boys. Risperidone was the most common drug in boys of all ages and in girls aged 5–11. In girls aged 12–17, aripiprazole and quetiapine were most common. The proportion of on-label antipsychotic use was 21% in girls and 15% in boys based in authorised product information and increased to 37% and 45%, respectively, when aligning with national guidelines. The use of antipsychotics has increased, with the proportion of girls starting treatment at the end of study period exceeding that of boys. A considerable proportion of prescriptions was off-label, even when considering national guidelines.
- 10 January 2026
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 35 (5) , 1487-1496
Open AccessDrug utilisation of antipsychotics and lithium in Sweden 2008–2021 – a nationwide study of children aged 5–17 years
Antipsychotics are mainly used for severe psychiatric disorders. Risperidone is the only antipsychotic approved for younger children. Aripiprazole is approved for older children, ziprasidone and lurasidone for adolescents. To describe paediatric utilisation of antipsychotic drugs in Sweden. Dispensations of antipsychotic drugs to children aged 5–17 years from 2008 to 2021 were analysed using the National Prescribed Drug Register and recorded diagnoses were obtained from the National Patient Register. Overall, dispensations of antipsychotics to children increased from 16.7 to 36.9/10,000 between 2008 and 2021. The increase was larger in girls, from 12.3 to 36.6/10,000. New users of antipsychotics increased by 121% in the same period, from 7.9 to 17.5/10.000. In 2019, in children aged 12–17, 63% of girls and 71% of boys were dispensed had at least three dispensations of antipsychotics, while the corresponding proportion in children aged 5–11 were 52% for girls and 63% for boys. Risperidone was the most common drug in boys of all ages and in girls aged 5–11. In girls aged 12–17, aripiprazole and quetiapine were most common. The proportion of on-label antipsychotic use was 21% in girls and 15% in boys based in authorised product information and increased to 37% and 45%, respectively, when aligning with national guidelines. The use of antipsychotics has increased, with the proportion of girls starting treatment at the end of study period exceeding that of boys. A considerable proportion of prescriptions was off-label, even when considering national guidelines.
- Open Access
- 22 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
SARS-CoV-2 vaccination and myositis in Norway and Sweden
Objective: The objective of this study was to characterize the risk of myositis after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with messenger ribonucleic acid (mRNA) or adenoviral vector vaccines. Methods: We conducted a population-based cohort study in Norway and Sweden of 13 million persons who turned 12 years or older in 2021 and were residents at the start of follow-up on 27 December 2020. The participants were followed until incident diagnosis of myositis, censoring, or the end of the study (21 May 2023). We used Poisson regression to estimate incidence rate ratios (IRRs) with 95% CIs, comparing rates in risk periods (day 0 up to and including day 180 after each dose) with rates in unvaccinated periods. Corrections for potential confounding were made by adjusting for sex, age, occupation (health-care worker), region, positive COVID-19 test, and comorbidities. Results: We observed 101 myositis events in 7 002 398 unvaccinated person-years and 99 myositis events within 180 days of any combination of mRNA vaccines (6 241 529 person-years), and 13 with the adenoviral vector vaccine (445 256 person-years). The adjusted IRRs for the 180-day risk periods following any combination of mRNA vaccines and the adenoviral vector vaccine were 0.84 (95% CI, 0.63–1.11) and 1.31 (0.72–2.36), respectively, compared with unvaccinated periods. The estimates for each specific first, second and third dose of mRNA were similar to the estimate of all doses combined. Conclusion: In this nationwide study of >13.6 million person-years in two countries, there were no signs of an increased risk of myositis after SARS-CoV-2 vaccination, neither after the mRNA vaccines nor after the adenoviral vector vaccine.
- 22 November 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Open AccessSARS-CoV-2 vaccination and myositis in Norway and Sweden
Objective: The objective of this study was to characterize the risk of myositis after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with messenger ribonucleic acid (mRNA) or adenoviral vector vaccines. Methods: We conducted a population-based cohort study in Norway and Sweden of 13 million persons who turned 12 years or older in 2021 and were residents at the start of follow-up on 27 December 2020. The participants were followed until incident diagnosis of myositis, censoring, or the end of the study (21 May 2023). We used Poisson regression to estimate incidence rate ratios (IRRs) with 95% CIs, comparing rates in risk periods (day 0 up to and including day 180 after each dose) with rates in unvaccinated periods. Corrections for potential confounding were made by adjusting for sex, age, occupation (health-care worker), region, positive COVID-19 test, and comorbidities. Results: We observed 101 myositis events in 7 002 398 unvaccinated person-years and 99 myositis events within 180 days of any combination of mRNA vaccines (6 241 529 person-years), and 13 with the adenoviral vector vaccine (445 256 person-years). The adjusted IRRs for the 180-day risk periods following any combination of mRNA vaccines and the adenoviral vector vaccine were 0.84 (95% CI, 0.63–1.11) and 1.31 (0.72–2.36), respectively, compared with unvaccinated periods. The estimates for each specific first, second and third dose of mRNA were similar to the estimate of all doses combined. Conclusion: In this nationwide study of >13.6 million person-years in two countries, there were no signs of an increased risk of myositis after SARS-CoV-2 vaccination, neither after the mRNA vaccines nor after the adenoviral vector vaccine.
- Open Access
- 12 August 2025
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 45 (9) , 665-675
Spontaneous Reports of Adverse Reactions with Fatal Outcomes After COVID-19 Vaccination During the National Vaccination Campaign in Sweden
Reports of suspected adverse drug reactions are of a great importance for the safety monitoring of new vaccines to identify potential safety risks promptly and to ensure necessary measures for risk mitigation. We reviewed the reports of fatal adverse drug reactions after coronavirus disease 2019 (COVID-19) vaccination with Comirnaty®, Spikevax®, and Vaxzevria® during the national vaccination campaign in Sweden. Swedish reports of suspected adverse drug reactions with fatal outcomes after COVID-19 vaccines were retrieved from the EudraVigilance database. Vaccination data were obtained from the National vaccination register. Reporting rates were calculated by dividing the number of adverse drug reaction reports with fatal outcomes by the number of people exposed to at least one dose of the COVID-19 vaccines or by the number of vaccine doses given. A causality assessment of adverse drug reaction reports was performed by clinically qualified reviewers. More than 26 million doses of COVID-19 vaccines were administered and 456 reports of suspected adverse drug reactions with fatal outcomes were reported during 27 December, 2020-31 May, 2023. The reporting rate was 5.7 fatal outcomes per 100,000 persons vaccinated with at least one dose of any COVID-19 vaccine or 1.7 per 100,000 vaccine doses given. Most of the fatalities were related to patients' pre-existing conditions, predominantly among people aged 70 years or older. Only ten of the reported fatalities (0.1 per 100,000 persons vaccinated) were assessed as consistent with a causal association to COVID-19 vaccination. Adverse drug reactions with fatal outcomes after COVID-19 vaccines in Sweden were very rare. No new safety concerns were observed in this study.
- 12 August 2025
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 45 (9) , 665-675
Open AccessSpontaneous Reports of Adverse Reactions with Fatal Outcomes After COVID-19 Vaccination During the National Vaccination Campaign in Sweden
Reports of suspected adverse drug reactions are of a great importance for the safety monitoring of new vaccines to identify potential safety risks promptly and to ensure necessary measures for risk mitigation. We reviewed the reports of fatal adverse drug reactions after coronavirus disease 2019 (COVID-19) vaccination with Comirnaty®, Spikevax®, and Vaxzevria® during the national vaccination campaign in Sweden. Swedish reports of suspected adverse drug reactions with fatal outcomes after COVID-19 vaccines were retrieved from the EudraVigilance database. Vaccination data were obtained from the National vaccination register. Reporting rates were calculated by dividing the number of adverse drug reaction reports with fatal outcomes by the number of people exposed to at least one dose of the COVID-19 vaccines or by the number of vaccine doses given. A causality assessment of adverse drug reaction reports was performed by clinically qualified reviewers. More than 26 million doses of COVID-19 vaccines were administered and 456 reports of suspected adverse drug reactions with fatal outcomes were reported during 27 December, 2020-31 May, 2023. The reporting rate was 5.7 fatal outcomes per 100,000 persons vaccinated with at least one dose of any COVID-19 vaccine or 1.7 per 100,000 vaccine doses given. Most of the fatalities were related to patients' pre-existing conditions, predominantly among people aged 70 years or older. Only ten of the reported fatalities (0.1 per 100,000 persons vaccinated) were assessed as consistent with a causal association to COVID-19 vaccination. Adverse drug reactions with fatal outcomes after COVID-19 vaccines in Sweden were very rare. No new safety concerns were observed in this study.
- 15 March 2025
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 39 (2) , 143-145
Compliance with Cyproterone Contraindications and Meningioma Risk: Resource-Efficient Use of Aggregated Statistics from Swedish National Health Registers
- 15 March 2025
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 39 (2) , 143-145
Compliance with Cyproterone Contraindications and Meningioma Risk: Resource-Efficient Use of Aggregated Statistics from Swedish National Health Registers
- Open Access
- 13 March 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 81 (5) , 739-753
Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region—a register-based cross-sectional study
Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained considerable media attention, but there is limited knowledge about those receiving the drugs. This study aimed to assess demographic characteristics and previous diagnoses in patients dispensed GLP-1 RAs in Region Stockholm, Sweden, between 2019 and 2023, with a focus on off-label prescribing. Methods: This was a register-based cross-sectional study including all inhabitants in Region Stockholm, Sweden, who were dispensed a GLP-1 RA between 2019 and 2023. Patient characteristics were assessed through record linkage with administrative healthcare data on demographics, healthcare consultations, diagnoses, and other dispensed drugs. Results: The prevalence proportion of GLP-1 RA dispensations in Region Stockholm increased from 4.7 patients/1000 inhabitants in 2019 to 17.5 patients/1000 inhabitants in 2023, and the incidence proportion from 1.8 patients/1000 inhabitants in 2019 to 7.4 patients/1000 inhabitants in 2023. GLP-1 RAs have become more common among a younger and female population, with women constituting 47% of incident patients in 2019 compared to 53% in 2023. The most common diagnosis shifted from type 2 diabetes mellitus (T2DM) (82% in 2019) to obesity (47% in 2023). During the same period, obesity without T2DM notably increased from 10 to 31%. Almost one-third (31%) of all patients dispensed the drugs in 2023 had no recorded diagnosis of either diabetes or obesity, compared to 8% in 2019. Conclusion: This study showed an increase in the dispensation of GLP-1 RA, with characteristics of patients changing towards a higher degree of off-label use. The effectiveness and safety of the increasing prescriptions warrant future studies.
- 13 March 2025
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 81 (5) , 739-753
Open AccessPrescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region—a register-based cross-sectional study
Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained considerable media attention, but there is limited knowledge about those receiving the drugs. This study aimed to assess demographic characteristics and previous diagnoses in patients dispensed GLP-1 RAs in Region Stockholm, Sweden, between 2019 and 2023, with a focus on off-label prescribing. Methods: This was a register-based cross-sectional study including all inhabitants in Region Stockholm, Sweden, who were dispensed a GLP-1 RA between 2019 and 2023. Patient characteristics were assessed through record linkage with administrative healthcare data on demographics, healthcare consultations, diagnoses, and other dispensed drugs. Results: The prevalence proportion of GLP-1 RA dispensations in Region Stockholm increased from 4.7 patients/1000 inhabitants in 2019 to 17.5 patients/1000 inhabitants in 2023, and the incidence proportion from 1.8 patients/1000 inhabitants in 2019 to 7.4 patients/1000 inhabitants in 2023. GLP-1 RAs have become more common among a younger and female population, with women constituting 47% of incident patients in 2019 compared to 53% in 2023. The most common diagnosis shifted from type 2 diabetes mellitus (T2DM) (82% in 2019) to obesity (47% in 2023). During the same period, obesity without T2DM notably increased from 10 to 31%. Almost one-third (31%) of all patients dispensed the drugs in 2023 had no recorded diagnosis of either diabetes or obesity, compared to 8% in 2019. Conclusion: This study showed an increase in the dispensation of GLP-1 RA, with characteristics of patients changing towards a higher degree of off-label use. The effectiveness and safety of the increasing prescriptions warrant future studies.
- Open Access
- 15 October 2024
- Published by Elsevier in Vaccine: X
- Vol. 21, 100571
Pulmonary embolism after SARS-CoV-2 vaccination
- 15 October 2024
- Published by Elsevier in Vaccine: X
- Vol. 21, 100571
Open AccessPulmonary embolism after SARS-CoV-2 vaccination